spacer
home > epc > spring 2002 > clinical trials and new drug applications in japan
PUBLICATIONS
European Pharmaceutical Contractor

Clinical Trials and New Drug Applications in Japan

The Common Technical Document (CTD) is a major step towards internationally recognised marketing authorisation applications, but its success will be affected by processes at a national level. In Japan, a number of recent clinical, ethical, regulatory and review changes also serve to provide even better access to this important region.

There has been considerable change in the Japanese regulatory framework over the last five years or so, driven by external (ICH) and internal (government) factors. The result is more effective, transparent and manageable approval processes.

With a population of 125 million (1), a recent international agreement on the CTD, and significant inclusion of other ICH steps, Japan represents a sizeable and accessible marketplace for research and marketing - more than ever before. In the mid- to late nineties, in excess of 7,000 ethical, over-the-counter (OTC) and quasi-drug manufacturing licences were held in Japan (1,2). With that in mind, the essential steps to obtain approval for clinical trials and to obtain marketing authorisation are described below.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tony Mitchell, Director of Regulatory Affairs at Origin Pharmaceutical Services Limited

Dr Tony Mitchell is Director of Regulatory Affairs and Strategic Services at Origin Pharmaceutical Services Limited.

He has considerable experience in the international registration of pharmaceutical products. He previously held regulatory positions at Fisons Pharmaceuticals, British Biotech Pharmaceuticals Limited and Pharmakopius, the international contract research organisation.

spacer
Dr Tony Mitchell
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement